Marital status, race increase survival rate significantly for Stage III non-small cell lung cancer patients

September 6, 2012

A study of survival data for Stage III, non-small cell lung cancer (NSCLC) patients at the University of Maryland's Greenebaum Cancer Center in Baltimore indicates that marital status and race can significantly impact patient survival rates, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC), and The University of Chicago.

This study reviewed the records of 168 patients with NSCLC who were treated with curative intent using chemotherapy and radiation at the Greenebaum Cancer Center from January 2000 to December 2010. The median survival rate for all patients was 13 months, with three-year survival rates of 21 percent.

Married women had the best three-year survival rate of 46 percent, and single men had the worst three-year survival rate of 3 percent. Married patients had improved survival compared to single patients—33 percent vs. 10 percent. Single females and married men had intermediate overall survival of 25 percent. Race also appears to play a role—married white patients had the best survival of 40 percent, and married black patients had a 26 percent three-year survival rate.

This study's results reinforce the critical role of spouses and caregivers in patient survival, and they are consistent with similar studies of other site-specific cancers, including head and neck and . The authors hypothesize that caregivers provide not only daily care but logistical support to help manage the treatment plan, compliance with the treatment plan and more accurate reporting of patient symptoms.

"While we were not surprised by these results, they confirm the positive impact of spousal support on patient survival," said lead author Elizabeth Nichols, MD, a resident in the department of at the University of Maryland Medical Center in Baltimore. "These findings also demonstrate the need for improved support of cancer patients and their spouses in order to continue to improve ."

Explore further: Married lung cancer patients survive longer than single patients after treatment

More information: The abstract, "Marital Status is an Independent Predictor of Survival for Patients Undergoing Definitive Chemoradiation for Stage III Non-Small Cell Lung Cancer," will be presented during the Poster Viewing at 5:00 p.m., Central time on September 6, 2012.

Related Stories

Married lung cancer patients survive longer than single patients after treatment

September 6, 2012
Married patients with locally advanced lung cancer are likely to survive longer after treatment than patients who are single, according to a study by researchers at the University of Maryland Marlene and Stewart Greenebaum ...

Brain radiation after lung cancer treatment reduces risk of cancer spreading

September 6, 2012
Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); ...

Hispanic lung cancer patients have higher survival than non-Hispanic white patients

September 6, 2012
Analysis of non-small cell lung cancer (NSCLC) patient records in the California Cancer Registry (CCR) database during the 20-year period of 1988-2008 indicates that Hispanics/Latinos with NSCLC have a higher overall survival ...

Adding bavituximab to second-line chemotherapy doubles response rate

September 6, 2012
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) ...

Stage I NSCLC patients who receive radiation therapy are surviving longer

September 6, 2012
Stage I, non-small cell lung cancer (NSCLC) patients who received radiation therapy have an increased median survival of 21 months compared to 16 months, and the percentage of patients who receive no treatment declined from ...

Standard chemotherapy provides higher survival rate than experimental in lung cancer patients

September 6, 2012
Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.